BJX1 Stock Overview
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BioLife Solutions, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.60 |
| 52 Week High | US$22.40 |
| 52 Week Low | US$8.30 |
| Beta | 1.69 |
| 1 Month Change | -9.83% |
| 3 Month Change | 0.65% |
| 1 Year Change | -3.70% |
| 3 Year Change | -45.34% |
| 5 Year Change | 1.80% |
| Change since IPO | 729.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| BJX1 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 11.4% | -0.9% | 0.5% |
| 1Y | -3.7% | -11.6% | 1.3% |
Return vs Industry: BJX1 exceeded the German Life Sciences industry which returned -9% over the past year.
Return vs Market: BJX1 underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| BJX1 volatility | |
|---|---|
| BJX1 Average Weekly Movement | 6.3% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BJX1 has not had significant price volatility in the past 3 months.
Volatility Over Time: BJX1's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 412 | Rod de Greef | www.biolifesolutions.com |
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
BioLife Solutions, Inc. Fundamentals Summary
| BJX1 fundamental statistics | |
|---|---|
| Market cap | €725.91m |
| Earnings (TTM) | -€61.92m |
| Revenue (TTM) | €133.56m |
5.3x
P/S Ratio-11.5x
P/E RatioIs BJX1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BJX1 income statement (TTM) | |
|---|---|
| Revenue | US$143.27m |
| Cost of Revenue | US$96.52m |
| Gross Profit | US$46.75m |
| Other Expenses | US$113.18m |
| Earnings | -US$66.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.47 |
| Gross Margin | 32.63% |
| Net Profit Margin | -46.36% |
| Debt/Equity Ratio | 7.4% |
How did BJX1 perform over the long term?
See historical performance and comparison